ACADIA Pharmaceuticals Inc. (ACAD) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in San Diego, CA, United States. The current CEO is Catherine E. Owen Adams.
ACAD has IPO date of 2004-05-27, 653 full-time employees, listed on the NASDAQ Global Select, a market capitalization of $3.75B.
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company headquartered in San Diego, California, specializing in the development and commercialization of small molecule drugs for central nervous system disorders. The company's flagship product, NUPLAZID (pimavanserin), is approved for treating hallucinations and delusions associated with Parkinson's disease psychosis. ACADIA's pipeline includes multiple late-stage candidates such as pimavanserin for Alzheimer's disease psychosis and schizophrenia, Trofinetide for Rett syndrome, ACP-044 for acute and chronic pain management, and ACP-319 for cognitive impairment in schizophrenia and Alzheimer's disease. Founded in 1993, ACADIA remains focused on addressing significant unmet medical needs in neuropsychiatric and neurological conditions.
